Cargando…
Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
INTRODUCTION: Low-dose aspirin or clopidogrel, statins, renin–angiotensin system inhibitors, and beta blockers are the cornerstone therapy for cardiovascular prevention in patients with coronary heart disease. Using only single-antiplatelet therapy for secondary prevention in patients with stable co...
Autores principales: | Debasu, Zenaw, Kedir, Hanan Muzeyin, Tadesse, Tamrat Assefa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480577/ https://www.ncbi.nlm.nih.gov/pubmed/36118183 http://dx.doi.org/10.2147/IJGM.S383485 |
Ejemplares similares
-
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021) -
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022) -
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022) -
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019) -
Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review
por: Kedir, Hanan Muzeyin, et al.
Publicado: (2021)